Hear ye! Hear ye! I have an announcement to make. About 3 months ago, a committee formed to explore the possibility of creating a new conference series for adults with type 1 diabetes. Most conferences are currently geared towards all types of diabetes, but a group of us felt there should be more for the unique challenges that are posed to adults living with type 1.

With that in mind, we are conducting an interest study for the conference. Who would you like to see at the conference? Tell us what is missing from Type 1 diabetes (besides the obvious **cure**). This will help us with programming, as well as securing sponsorships for the event. Besides giving you all you want from the latest and greatest in type 1 diabetes - you have a chance to leave your mark on this revolutionary event. At the end of the survey, there is a question about creating a name for the conference. The committee will choose the winning name. The winner will receive an autographed copy of Know Your Numbers, by Amy Tenderich and Dr. Richard Jackson. The second and third places prizes are a Six Until Me mug and a Diabetes Mine mug, donated by Kerri Morrone and Amy Tenderich.

The survey closes on Friday, September 7, 2007 so don't miss your opportunity to voice your opinion. Take the survey today!!

In the next 3 to 5 years, we will have a new generation of control upon us providing continuous glucose monitoring. Some of these marvelous technologies will not require a drop of blood, while others will embody the tried-and-true stick-to-itiveness we all know and loathe.

Please join me as we browse the isles of things to come (and things now available) for continuous glucose monitoring.

The DexCom STS Continuous Glucose Monitoring System is a glucose sensor that reports glucose values every 5 minutes for up to 72 hours. The sensor is inserted in the abdomen. After a 2 hour start-up period, the STS System is calibrated with 2 fingerstick measurements taken by a traditional glucose meter. Checkout Amy Tenderich's review on Diabetes Mine of the DexCom Continuous Glucose Monitoring Sytem.

MiniMed Medtronic has 3 different versions: the Gold, the Guardian RT, and the Paradigm Real-Time Continuous Monitor.

Menarini GlucoDay S is a device worn by the patient for the continuous monitoring of glucose in the subcutaneous interstitial fluid. Monitoring is performed via insertion in the abdominal region of a microfibre for dialysis having the diameter of a human hair. Inside the microfibre a solution transports the patient's glucose to a biosensor within the instrument.

M-Biotech Glucose Biosensor is a minimally invasive implantation for painless and convenient monitoring. The key feature of our efficient Glucose Biosensor is the combination of a glucose-sensitive hydrogel and a miniature pressure sensor. Glucose-responsive hydrogels are biocompatible materials that either swell or contract when the glucose concentrations change in the body fluid surrounding the hydrogel.

The PreciSense System includes a microcapsule placement unit and a light detecting non-invasive reader unit. The microcapsule placement unit poses the right dose of glucose-responding microcapsules in the upper layer of the skin, painlessly. The glucose assay components in the microcapsules generate a fluorescence signal that corresponds to the glucose level. The non-invasive reader unit monitors this glucose binding event through FRET, Fluorescence Resonance Energy Transfer, which is directly related to the concentration of glucose.

Sensors for Medicine and Science glucose sensor is implanted under the skin in a short outpatient procedure. The sensor automatically measures interstitial glucose every few minutes, without any user intervention. The sensor implant will communicate wirelessly with a small external reader.

Synthetic Blood Implanted Glucose Biosensor claims to offer significantly more accurate glucose readings in a range of 30-500 mg/dl. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. The most accurate glucose monitor available, the implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

GlucoLight Corporation is developing a low-cost non-invasive blood glucose monitor for home use by diabetic patents. GlucoLight's unique optical approach, microScatterTM (microscatter) technology, is based on patented technologies in the area of Optical Coherence Tomography (OCT) and Low Coherence Interferometry (LCI). There is a working prototype with published clinical data on healthy volunteers.

The GlucoWatch G2 Biographer was approved to detect glucose level trends and track patterns in people with diabetes. It must be used along with conventional blood glucose monitoring of blood samples. The device, which looks like a wristwatch, pulls body fluid from the skin using small electric currents. It can provide six measurements per hour for 13 hours. (See David Mendosa's review).

Altea Therapeutics is working on the next generation of insulin delivery in the form of an insulin patch. Altea is developing, both 12 and 24-hour, patches to provide controlled, continuous delivery of basal insulin in people with type 1 and type 2 diabetes. This will allow uninterrupted, measured delivery of insulin through the skin, by way of an adhesive sticker no larger than a few centimeters. For those already diagnosed with diabetes, this could be the band aid to quell their fear of needles, as well as effectively sticking to an insulin regimen. For those in limbo, diagnosed as pre-diabetes, this may be the answer your body needs to supplement your insulin reserves.

The PassPort^TM System is comprised of a single-use disposable PassPort^TM Patch and a re-useable handheld applicator. The patch is made of a metallic grid containing powder insulin. The handheld applicator releases a single pulse of electrical energy that converts into thermal energy, painlessly fastening the grid to the skin surface. The electronic pulse also creates porous channels to deliver the insulin through the skin. No injections, application in milliseconds, and continuous basal delivery of insulin throughout the day.

This breakthrough technology is about freedom, convenience and ultimately better control. The PassPort^TM System replaces injections thereby enhancing compliance in patients. This directly correlates to better diabetes control. Upon FDA approval, I can only hope this dandy contraption is warmly welcomed into your doctor's office. As every doctor continues searching for the Holy Grail of patient compliance, tell him to check this out. Talk about patching things up!